Abstract
Aspirin has long been the mainstay of primary and secondary prevention against myocardial infarction and ischemic cerebrovascular events. However, the incremental value of aspirin for primary prevention has recently been subject to debate given data from recent large clinical trials, as the net clinical benefit is small. In secondary prevention, aspirin is still strongly recommended.
Efforts in obtaining more efficient antiplatelet agents and to reduce cardiovascular morbidity and mortality have led to the development of new adenosine diphosphate (ADP) receptor antagonists, which are superior to clopidogrel. New generation antiplatelet drugs i.e. prasugrel and ticagrelor aim to reduce atherothrombotic events, mortality and stent thrombosis, as well as overcome low- or non-response to clopidogrel. Further agents with antiplatelet properties are being investigated at present.
This overview aims to give insights into the rapidly changing field of antiplatelet strategies in cardiovascular diseases.
Keywords: Atherothrombosis, cardiovascular disease, primary prevention, secondary prevention, novel antithrombotics, acetyl salicylic acid, adenosine diphosphate (ADP), infarction, ischemic cerebrovascular, clopidogrel
Current Pharmaceutical Design
Title: Antiplatelet Therapy in Atherothrombotic Cardiovascular Diseases for Primary and Secondary Prevention: A Focus on Old and New Antiplatelet Agents
Volume: 18 Issue: 6
Author(s): Burak Pamukcu, Kurt Huber and Gregory Y.H. Lip
Affiliation:
Keywords: Atherothrombosis, cardiovascular disease, primary prevention, secondary prevention, novel antithrombotics, acetyl salicylic acid, adenosine diphosphate (ADP), infarction, ischemic cerebrovascular, clopidogrel
Abstract: Aspirin has long been the mainstay of primary and secondary prevention against myocardial infarction and ischemic cerebrovascular events. However, the incremental value of aspirin for primary prevention has recently been subject to debate given data from recent large clinical trials, as the net clinical benefit is small. In secondary prevention, aspirin is still strongly recommended.
Efforts in obtaining more efficient antiplatelet agents and to reduce cardiovascular morbidity and mortality have led to the development of new adenosine diphosphate (ADP) receptor antagonists, which are superior to clopidogrel. New generation antiplatelet drugs i.e. prasugrel and ticagrelor aim to reduce atherothrombotic events, mortality and stent thrombosis, as well as overcome low- or non-response to clopidogrel. Further agents with antiplatelet properties are being investigated at present.
This overview aims to give insights into the rapidly changing field of antiplatelet strategies in cardiovascular diseases.
Export Options
About this article
Cite this article as:
Pamukcu Burak, Huber Kurt and Y.H. Lip Gregory, Antiplatelet Therapy in Atherothrombotic Cardiovascular Diseases for Primary and Secondary Prevention: A Focus on Old and New Antiplatelet Agents, Current Pharmaceutical Design 2012; 18 (6) . https://dx.doi.org/10.2174/138161212799277716
DOI https://dx.doi.org/10.2174/138161212799277716 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Metabolic Syndrome and Chronic Liver Disease
Current Pharmaceutical Design Nutraceuticals, Nutritional Therapy, Phytonutrients, and Phytotherapy for Improvement of Human Health: A Perspective on Plant Biotechnology Application
Recent Patents on Biotechnology Hypoxia-Inducible Factor: A Potential Therapeutic Target for Rheumatoid Arthritis
Current Drug Targets Lipid Mediator Profiling in Pulmonary Disease
Current Pharmaceutical Biotechnology Pathophysiological Basis for Anticoagulant and Antithrombotic Therapy in Pulmonary Hypertension
Cardiovascular & Hematological Agents in Medicinal Chemistry The Deadly Quartet (Covid-19, Old Age, Lung Disease, and Heart Failure) Explains Why Coronavirus-Related Mortality in Northern Italy Was So High
Current Cardiology Reviews Angiotensin Mediated Oxidative Stress and Neuroprotective Potential of Antioxidants and AT1 Receptor Blockers
Mini-Reviews in Medicinal Chemistry Advanced Glycation: A Novel Outlook on Atherosclerosis
Current Pharmaceutical Design Anorexia of Aging
Current Nutrition & Food Science The Role of Blood-Brain Barrier Transporters in Pathophysiology and Pharmacotherapy of Stroke
Current Pharmaceutical Design Emerging Molecular Targets for Imaging of Atherosclerotic Plaque using Positron Emission Tomography
Current Radiopharmaceuticals The 9p21 Locus and its Potential Role in Atherosclerosis Susceptibility; Molecular Mechanisms and Clinical Implications
Current Pharmaceutical Design Measurement of Physical Changes in the Myocardium for Development of Novel Methods for Diagnosing Ischemia
Current Cardiology Reviews Soy Isoflavones and Cardiovascular Disease Epidemiological, Clinical and -Omics Perspectives
Current Pharmaceutical Biotechnology Antihypertensive Drug Treatment and Circadian Blood Pressure Rhythm: A Review of the Role of Chronotherapy in Hypertension
Current Pharmaceutical Design Inflammatory Biomarkers Predicting Events in Atherosclerosis
Current Medicinal Chemistry Relationship of High-Sensitivity C-Reactive Protein Concentrations and Systolic Heart Failure
Current Vascular Pharmacology Palladium-Catalyzed Oxyarylation, Azaarylation and α-Arylation Reactions in the Synthesis of Bioactive Isoflavonoid Analogues
Current Organic Synthesis Haptoglobin Polymorphism and Lacunar Stroke
Current Neurovascular Research Targeting Adenosine Signaling to Treatment of Diabetic Nephropathy
Current Drug Targets